A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-04-07
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in
subjects with locally advanced (unresectable) and/or metastatic solid tumors that are
refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for
that indication).